Getting your player ready...
Shares of Boulder-based Array BioPharma Inc. rose 13 percent in regular trading Monday after it announced an agreement granting Amgen Inc. exclusive worldwide rights to its small-molecule glucokinase activator program.
The program includes ARRY-403, which is being tested in a Phase 1 clinical trial in patients with Type 2 diabetes.
Array will receive an upfront payment of $60 million and additional payments as the compound reaches clinical and commercial milestones.
